Charles River Laboratories International (NYSE:CRL – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 9.900-10.200 for the period, compared to the consensus EPS estimate of 10.990. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.2 billion. Charles River Laboratories International also updated its FY24 guidance to $9.90-10.20 EPS.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Charles River Laboratories International in a research report on Thursday, June 6th. They issued a buy rating and a $290.00 price target for the company. TD Cowen dropped their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a hold rating on the stock in a report on Monday, May 13th. StockNews.com downgraded Charles River Laboratories International from a buy rating to a hold rating in a report on Friday, June 14th. Mizuho assumed coverage on Charles River Laboratories International in a report on Friday, June 7th. They issued a neutral rating and a $235.00 price objective on the stock. Finally, Argus restated a hold rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of Hold and an average target price of $252.29.
View Our Latest Stock Analysis on CRL
Charles River Laboratories International Stock Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 10.99 EPS for the current year.
Insider Buying and Selling at Charles River Laboratories International
In other news, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.30% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- How to Effectively Use the MarketBeat Ratings Screener
- What Are Bonds? A High-Level Overview
- What are earnings reports?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Invest in the Best Canadian Stocks
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.